A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
A clinical trial for potential new therapy Ocrelizumab is recruiting in Irish centres. Ocrelizumab has been found to have potential benefits for both relapsing remitting MS and primary progressive MS, but this study is for people with RRMS only.
Potential participants must meet the following criteria:
- Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria
- Have a length of disease duration, from first symptom, of less than (<) 10 years
- Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy
- Suboptimal disease control while on a DMT
- Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening
- For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug
This clinical trial is being carried out in St Vincent’s Hospital Dublin, Beaumont Hospital Dublin and Cork University Hospital. However, people attending other treatment centres can be referred into the trial, provided their Neurologist agrees that they are suitable.
If you want to find out more about this trial or find out if you may be suitable, you must discuss this with your Neurologist. Further information about the trial can be found here